ScreenerHero

XBIOXenetic Biosciences, Inc.

NAS · US · Healthcare · Biotechnology · xeneticbio.com
3.590USD+6.85%Mkt Cap: 8.41M $P/E: —

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. Its DNase technology targets neutrophil extracellular traps (NETS), which are involved in cancer…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap8.41M $
Enterprise Value1.47M $
Revenue (TTM)3.26M $
Gross Profit3.26M $
Net Income (TTM)-2.68M $
Revenue/Share1.570 USD
Last Price3.590 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees2
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-5.14
PEG—
EV/EBITDA—
EV/Revenue0.45
P/S2.44
P/B1.12
EPS (TTM)-1.19
EPS (Forward)-0.66
52W Range
1.90014% of range13.93
52W High13.93 USD
52W Low1.900 USD
Profitability
Gross Margin100.00%
Oper. Margin-147.09%
EBITDA Margin0.00%
Profit Margin-90.07%
ROE-36.25%
ROA-32.05%
Growth
Revenue Growth12.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-2.29M $
CapEx (TTM)—
FCF Margin-36.03%
FCF Yield-13.97%
Net Debt-6.47M $
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio7.43
Quick Ratio7.23
Book Value/Sh3.033 USD
Cash/Share2.762 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateJun 25, 2019
Splits
Last Split1:10
Split DateMay 15, 2023
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.2.34M
Float1.89M
Insiders15.42%
Institutions6.49%
Short Interest
Short Ratio0.6d
Short % Float0.51%
Short % Out.0.49%
Shares Short11.31K
Short (prev mo.)23.59K
Technical
SMA 502.910 (+23.4%)
SMA 2002.729 (+31.5%)
Beta2.15
S&P 52W Chg18.16%
Avg Vol (30d)51.89K
Avg Vol (10d)93.90K
Technical Indicators
RSI (14)73.0
MACD0.1641
MACD Signal0.0905
MACD Hist.+0.0737
BB Upper3.647 USD
BB Middle2.937 USD
BB Lower2.226 USD
BB Width48.38%
ATR (14)0.2112 USD
Vol Ratio (20d)1.29x